Pre-clinical & clinical studies of breast cancer prevention with transdermal anti-progesterone agent

Project: Research project

Project Details


In the coming year, we will complete our pre-surgical window trial (NU-12B09, 2-10 weeks of telapristone 12.5 mg in Stage I-II breast cancer patients); initiate an NCI-funded comparison of oral and transdermal telapristone (CDB4124) in a window setting; and continue preclinical evaluation of CDB-4124 in comparison to classical and additional novel anti-progestins. However, the major focus of the experiments described below will be to generate data to support a Phase II prevention trial using telapristone in BRCA mutation carriers.
Effective start/end date10/1/149/30/16


  • Breast Cancer Research Foundation (Form 08/22/2014)


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.